Overview

Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine whether a significant pharmacokinetic interaction exists between rapamycin and sorafenib. This study will also look at the toxicity of the combination of rapamycin and sorafenib and the antitumor activity of the combination in subjects with advanced cancers.
Phase:
Phase 1
Details
Lead Sponsor:
University of Chicago
Collaborator:
Bayer
Treatments:
Everolimus
Niacinamide
Sirolimus
Sorafenib